Related Experiment Video
Updated: Sep 6, 2026
Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples
Published on: June 15, 2012
First-In-Human Rapid Removal of Circulating Tumor Cells in Solid Metastatic Neoplasia by Microbind Affinity Blood
Sanja Ilic1,2, Vedran Premuzic3,4
1ExThera Medical Corporation, Martinez, California, USA.
Introduction:
We conducted a first-in-human trial evaluating safety and the potential for combined pathogen and circulating tumor cell (CTC) removal in patients with solid metastatic cancers.
Methods:
The Seraph procedure was performed at a hemodialysis clinic on 10 consecutive patients with metastatic cancer whose liquid biopsy was positive for the epithelial cell adhesion molecule. All the patients exerted positive bacterial or fungal isolates.
Results:
We have demonstrated the ability of Seraph100® Filter to remove both pathogens and CTCs, with median reduction of 71% within 120 min, from patient blood.
Conclusion:
High-yield CTC clearance could potentially benefit patients in diagnostic and personalized treatment of cancer to be elucidated in further research.
